This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Affymax Announces Updates To Senior Leadership Team

Affymax, Inc. (Nasdaq: AFFY) today announced the promotion of Christine Conroy, Pharm.D., to senior vice president, Regulatory Affairs and Quality Assurance, as well as Tim Varacek to vice president, Sales and Account Management. The company also announced Robert F. Venteicher, Ph.D., will retire as Affymax’s senior vice president, technical operations effective March 31, 2013.

“We have made remarkable strides with OMONTYS in the past year, securing approval of this once-monthly erythropoiesis-stimulating agent and supporting its successful launch,” said John Orwin, chief executive officer of Affymax. “Christine played a critical role in our successful New Drug Application and regulatory review of OMONTYS and has demonstrated continued leadership in Corporate Quality and Regulatory Affairs as we transitioned to a commercial-stage company. On the commercial front, Tim has been instrumental in forging timely relationships with our key customers and leading our sales team in their efforts. We are pleased to have Christine’s and Tim’s pertinent experience and expertise on our senior management team.”

Dr. Conroy had served as vice president, Corporate Quality and Regulatory Affairs for Affymax since December 2011. She served as vice president Regulatory Affairs and Clinical Quality Assurance from July 2007 to November 2011, and she held positions with increasing levels of responsibility in Regulatory Affairs from October 2004 to July 2007. Before joining Affymax, Dr. Conroy held various senior level positions in the regulatory departments of Genitope Corporation and Roche Global Development. She started her career in the pharmaceutical industry in 1989 at Syntex Laboratories, Inc. in the Medical Services Department. She earned her Pharm.D. from the University of Kansas, School of Pharmacy, and her B.S. in pharmacy from the University of Colorado, School of Pharmacy.

Mr. Varacek had served as executive director, Sales and Account Management for Affymax since April 2011. Prior to joining Affymax, he served in various executive roles in Sales Management, and from January 2007 through March 2011 was responsible for managing national accounts for Amgen’s nephrology franchise. During his tenure at Amgen, he also served in various management positions within Marketing and Sales Operations. Prior to Amgen, Mr. Varacek held positions in Sales, Sales Management and Sales Training at Bristol-Myers Squibb Inc. Mr. Varacek earned a B.S. in Biology from Binghamton University.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs